| __timestamp | Bausch Health Companies Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 675200000 |
| Thursday, January 1, 2015 | 2682700000 | 771800000 |
| Friday, January 1, 2016 | 2810000000 | 1205500000 |
| Sunday, January 1, 2017 | 2582000000 | 1146500000 |
| Monday, January 1, 2018 | 2473000000 | 1125800000 |
| Tuesday, January 1, 2019 | 2554000000 | 1166100000 |
| Wednesday, January 1, 2020 | 2367000000 | 1175500000 |
| Friday, January 1, 2021 | 2624000000 | 1111400000 |
| Saturday, January 1, 2022 | 2625000000 | 1210100000 |
| Sunday, January 1, 2023 | 2917000000 | 1274600000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Bausch Health Companies Inc. and Perrigo Company plc have showcased contrasting trends in their SG&A expenditures.
From 2014 to 2023, Bausch Health consistently allocated a higher percentage of its revenue to SG&A expenses, peaking in 2023 with a 44% increase from 2014. In contrast, Perrigo demonstrated a more conservative approach, with a 47% increase over the same period. This divergence highlights Bausch Health's aggressive market strategies compared to Perrigo's more measured approach.
These insights provide a window into each company's operational priorities and strategic focus, offering investors and analysts a deeper understanding of their financial health and market positioning.
Comparing SG&A Expenses: Merck & Co., Inc. vs Perrigo Company plc Trends and Insights
SG&A Efficiency Analysis: Comparing Amgen Inc. and Perrigo Company plc
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Perrigo Company plc
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Perrigo Company plc
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?